Skip to content

Cefprozil

FDA-approved product (tablet, oral), marketed as Cefprozil, Cefzil.

Registered studies
16
Lab records
5
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Cefprozil
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Chronic bronchitis
  • Infection
  • Otitis media
  • Pharyngitis
  • Recurrent tonsillitis
  • Sinusitis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Second-generation cephalosporins
FDA pharmacologic class
Cephalosporin Antibacterial FDA label ↗
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01DC10; FDA class Cephalosporin Antibacterial

Repurposing investigation

Cefprozil is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA98.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli80.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae87.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis38.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

16registered studies name this medicine, for any condition. See them below.

Experimental

  • MRSA: measured active in 2 of 2 lab records
  • E. coli: measured active in 2 of 2 lab records
  • K. pneumoniae: measured active in 1 of 1 lab record
Show the 5 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Cefprozil with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP

    NCT06494072 · start 2024-08-22

    Registered record
    Registry ID
    NCT06494072
    Conditions
    Community Acquired Pneumonia in Children
    Interventions
    Ampicillin for Injection; Ceftriaxone for Injection; Amoxicillin; Ampicillin / Sulbactam Injection; Amoxicillin-clavulanate; Clindamycin; Cefprozil; Levofloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2024-08-22
    Completion
    2028-05
    Enrolment
    236

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCommunity Acquired Pneumonia in Children
    InterventionAmpicillin for Injection; Ceftriaxone for Injection; Amoxicillin; Ampicillin / Sulbactam Injection +4 more
    PhasePhase 4
    Registry statusRecruiting
  • Bioequivalence of Cefprozil Granule in Healthy Chinese Volunteers

    NCT04414254 · start 2018-09-11

    Registered record
    Registry ID
    NCT04414254
    Conditions
    Healthy Volunteers
    Interventions
    Cefprozil 125mg/5ml Susp; Cefprozil granule (125mg)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-09-11
    Completion
    2019-01-30
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionCefprozil 125mg/5ml Susp; Cefprozil granule (125mg)
    PhasePhase 1
    Registry statusCompleted
  • Patients Response to Early Switch To Oral:Osteomyelitis Study

    NCT02099240 · start 2014-03-06

    Registered record
    Registry ID
    NCT02099240
    Conditions
    Osteomyelitis
    Interventions
    oral antibiotics; intravenous antibiotics
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Terminated
    Start
    2014-03-06
    Completion
    2018-11-07
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOsteomyelitis
    Interventionoral antibiotics; intravenous antibiotics
    PhaseEarly phase 1
    Registry statusTerminated
  • Comparative Effectiveness of Antibiotics for Respiratory Infections

    NCT02297815 · start 2014-01

    Registered record
    Registry ID
    NCT02297815
    Conditions
    Acute Otitis Media; Acute Sinusitis; Group A Streptococcal Pharyngitis
    Interventions
    Broad-spectrum antibiotics; Narrow-spectrum antibiotics
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2014-01
    Completion
    2016-04
    Enrolment
    2,472

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Otitis Media; Acute Sinusitis; Group A Streptococcal Pharyngitis
    InterventionBroad-spectrum antibiotics; Narrow-spectrum antibiotics
    PhaseNot recorded
    Registry statusCompleted
  • Bioequivalence Study of Cefprozil 250 mg/ 5mL Powder For Oral Suspension Under Fasting Conditions

    NCT00778557 · start 2005-06

    Registered record
    Registry ID
    NCT00778557
    Conditions
    Healthy
    Interventions
    CEFPROZIL FOR ORAL SUSPENSION USP 250 mg/ 5 mL
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2005-06
    Completion
    2005-07
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionCEFPROZIL FOR ORAL SUSPENSION USP 250 mg/ 5 mL
    PhaseNot applicable
    Registry statusCompleted
  • Bioequivalence Study of Cefprozil 250 mg/ 5mL Powder For Oral Suspension Under Fed Conditions

    NCT00778739 · start 2005-06

    Registered record
    Registry ID
    NCT00778739
    Conditions
    Healthy
    Interventions
    CEFPROZIL FOR ORAL SUSPENSION USP 250 mg/ 5 mL
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2005-06
    Completion
    2005-07
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionCEFPROZIL FOR ORAL SUSPENSION USP 250 mg/ 5 mL
    PhaseNot applicable
    Registry statusCompleted
  • Bioequivalence Study of Cefprozil Tablets, USP 500 mg Undef Fed Conditions

    NCT00778245 · start 2005-05

    Registered record
    Registry ID
    NCT00778245
    Conditions
    Healthy
    Interventions
    cefprozil 500mg tablets
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2005-05
    Completion
    2005-10
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    Interventioncefprozil 500mg tablets
    PhaseNot applicable
    Registry statusCompleted
  • Bioequivalence Study of Cefprozil Tablets, USP 500 mg Under Fasting Conditions

    NCT00778778 · start 2005-05

    Registered record
    Registry ID
    NCT00778778
    Conditions
    Healthy
    Interventions
    cefprozil 500mg tablets
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2005-05
    Completion
    2005-08
    Enrolment
    27

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    Interventioncefprozil 500mg tablets
    PhaseNot applicable
    Registry statusCompleted
  • To Demonstrate the Relative Bioavailability of Cefzil 250 mg/5 ml Cefprozil Oral Suspension Fed Conditions

    NCT00881400 · start 2004-06

    Registered record
    Registry ID
    NCT00881400
    Conditions
    Healthy
    Interventions
    Cefprozil 250 mg/5 ml Oral Suspension (Sandoz, Austria); Cefzil (Cefprozil) 250 mg/5 ml Oral Suspension (Bristol-Myers Squibb, USA)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2004-06
    Completion
    2004-06
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionCefprozil 250 mg/5 ml Oral Suspension (Sandoz, Austria); Cefzil (Cefprozil) 250 mg/5 ml Oral Suspension (Bristol-Myers Squibb, USA)
    PhasePhase 1
    Registry statusCompleted
  • Cefprozil for Oral Suspension 250 mg/5 mL, Non-fasting

    NCT00835354 · start 2004-05

    Registered record
    Registry ID
    NCT00835354
    Conditions
    Healthy
    Interventions
    Cefprozil for oral suspension 250 mg/5 mL; CEFZIL® for Oral Suspension 250 mg/5mL
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2004-05
    Completion
    2004-05
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionCefprozil for oral suspension 250 mg/5 mL; CEFZIL® for Oral Suspension 250 mg/5mL
    PhasePhase 1
    Registry statusCompleted
  • To Demonstrate the Relative Bioavailability of Cefzil 250 mg/5 ml Cefprozil Oral Suspension Following a 10 ml Dose Fasting Conditions.

    NCT00881153 · start 2004-05

    Registered record
    Registry ID
    NCT00881153
    Conditions
    Healthy
    Interventions
    Cefprozil 250 mg/5 ml Oral Suspension (Sandoz GmbH); Cefzil (Cefprozil) 250 mg/5 ml Oral Suspension (Bristol-Myers Squibb)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2004-05
    Completion
    2004-06
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionCefprozil 250 mg/5 ml Oral Suspension (Sandoz GmbH); Cefzil (Cefprozil) 250 mg/5 ml Oral Suspension (Bristol-Myers Squibb)
    PhasePhase 1
    Registry statusCompleted
  • Cefprozil for Oral Suspension 250 mg/5 mL, Fasting

    NCT00835614 · start 2004-04

    Registered record
    Registry ID
    NCT00835614
    Conditions
    Healthy
    Interventions
    Cefprozil for oral suspension 250 mg/5 mL; CEFZIL® for Oral Suspension 250 mg/5mL
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2004-04
    Completion
    2004-04
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionCefprozil for oral suspension 250 mg/5 mL; CEFZIL® for Oral Suspension 250 mg/5mL
    PhasePhase 1
    Registry statusCompleted
  • To Demonstrate the Relative Bioavailability of Cefzil 500 mg Cefprozil Tablets Under Fasting Conditions

    NCT00881426 · start 2004-03

    Registered record
    Registry ID
    NCT00881426
    Conditions
    Healthy
    Interventions
    Cefprozil 500 mg Tablets (Sandoz GmbH); Cefzil (Cefprozil) 500 mg Tablets (Bristol-Myers Squibb)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2004-03
    Completion
    2004-04
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionCefprozil 500 mg Tablets (Sandoz GmbH); Cefzil (Cefprozil) 500 mg Tablets (Bristol-Myers Squibb)
    PhasePhase 1
    Registry statusCompleted
  • To Demonstrate the Relative Bioavailability of Cefzil 500 mg Cefprozil Tablets Under Fed Conditions

    NCT00881855 · start 2004-03

    Registered record
    Registry ID
    NCT00881855
    Conditions
    Healthy
    Interventions
    Cefprozil 500 mg Tablets (Sandoz, GmbH); Cefzil (Cefprozil) 500 mg Tablets (Bristol-Myers Squibb, USA)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2004-03
    Completion
    2004-04
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionCefprozil 500 mg Tablets (Sandoz, GmbH); Cefzil (Cefprozil) 500 mg Tablets (Bristol-Myers Squibb, USA)
    PhasePhase 1
    Registry statusCompleted
  • Cefprozil 500 mg Tablets Under Fasting Conditions

    NCT00840281 · start 2003-09

    Registered record
    Registry ID
    NCT00840281
    Conditions
    Healthy
    Interventions
    Cefzil® 500 mg tablets; Cefprozil 500 mg Tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2003-09
    Completion
    2003-09
    Enrolment
    38

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionCefzil® 500 mg tablets; Cefprozil 500 mg Tablets
    PhasePhase 1
    Registry statusCompleted